2306 related articles for article (PubMed ID: 12783009)
1. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?
Nahabedian MY; Tufaro AP; Manson PN
Ann Plast Surg; 2003 Jun; 50(6):601-6. PubMed ID: 12783009
[TBL] [Abstract][Full Text] [Related]
2. [Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma].
Keijzer R; Bril H; van der Loo EM; de Graaf PW
Ned Tijdschr Geneeskd; 2004 May; 148(18):884-8. PubMed ID: 15152391
[TBL] [Abstract][Full Text] [Related]
3. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
[TBL] [Abstract][Full Text] [Related]
4. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
5. [Sentinel lymph node biopsy in patients with melanoma].
Tomás-Mallebrera L; Rojo-España R; Marquina-Vila A; Gimeno-Clemente N; Morales-Suárez-Varela MM
Actas Dermosifiliogr; 2010 Jun; 101(5):428-36. PubMed ID: 20525486
[TBL] [Abstract][Full Text] [Related]
6. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
7. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
[TBL] [Abstract][Full Text] [Related]
8. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
9. Our experience of melanoma thickness as a predictor of outcome of sentinel node biopsy.
Homolak D; Vucetić B; Puljiz Z; Blajć I; Vurnek Zivković M; Situm M
Coll Antropol; 2008 Oct; 32 Suppl 2():57-60. PubMed ID: 19138008
[TBL] [Abstract][Full Text] [Related]
10. [Tumour regression is not predictive for higher risk of sentinel node involvement in thin melanomas (Breslow thickness < or = 1 mm)].
Kramkimel N; Maubec E; Boitier F; Cavalcanti A; Beldi M; Mamelle G; Kolb F; Duvillard P; Avril MF
Ann Dermatol Venereol; 2010 Apr; 137(4):276-80. PubMed ID: 20417360
[TBL] [Abstract][Full Text] [Related]
11. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
[TBL] [Abstract][Full Text] [Related]
12. Tumour regression does not increase the risk of sentinel node involvement in thin melanomas.
Cecchi R; Pavesi M; Buralli L; Innocenti S; De Gaudio C
Chir Ital; 2008; 60(2):257-60. PubMed ID: 18689175
[TBL] [Abstract][Full Text] [Related]
13. The risk of regional lymph node metastases in patients with melanoma less than 1.0 mm thick: recommendations for sentinel lymph node biopsy.
Zapas JL; Coley HC; Beam SL; Brown SD; Jablonski KA; Elias EG
J Am Coll Surg; 2003 Sep; 197(3):403-7. PubMed ID: 12946795
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors of cutaneous melanoma in relation to metastasis at the sentinel lymph node: a case-controlled study.
Sartore L; Papanikolaou GE; Biancari F; Mazzoleni F
Int J Surg; 2008 Jun; 6(3):205-9. PubMed ID: 18417434
[TBL] [Abstract][Full Text] [Related]
15. Sentinel lymph node biopsy in thin melanoma patients.
Hershko DD; Robb BW; Lowy AM; Ahmad SA; Ramadas GH; Soldano DA; Sussman JJ
J Surg Oncol; 2006 Mar; 93(4):279-85. PubMed ID: 16496355
[TBL] [Abstract][Full Text] [Related]
16. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
[TBL] [Abstract][Full Text] [Related]
17. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study.
Koskivuo I; Talve L; Vihinen P; Mäki M; Vahlberg T; Suominen E
Ann Surg Oncol; 2007 Dec; 14(12):3566-74. PubMed ID: 17924169
[TBL] [Abstract][Full Text] [Related]
18. Lymphatic invasion detected by D2-40/S-100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma.
Petitt M; Allison A; Shimoni T; Uchida T; Raimer S; Kelly B
J Am Acad Dermatol; 2009 Nov; 61(5):819-28. PubMed ID: 19836642
[TBL] [Abstract][Full Text] [Related]
19. The role of sentinel lymph node biopsy in the management of thin melanoma.
Wong SL
Am J Surg; 2005 Aug; 190(2):196-9. PubMed ID: 16023430
[TBL] [Abstract][Full Text] [Related]
20. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?
Gajdos C; Griffith KA; Wong SL; Johnson TM; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
Cancer; 2009 Dec; 115(24):5752-60. PubMed ID: 19827151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
